新辅助化疗后前哨淋巴结阳性乳腺癌:区域复发率与腋窝清扫的关系
本研究回顾161例新辅助化疗后前哨淋巴结活检阳性乳腺癌患者,比较仅前哨淋巴结活检与加行腋窝淋巴结清扫的结局。
要点
- 新辅助化疗后前哨淋巴结阳性者,省略腋窝清扫未损害局部、区域或远处控制及总生存。
- 仅前哨淋巴结活检组3年区域控制率92.6%,加腋窝清扫组96.4%,差异无统计学意义。
核心结论
- 经仔细选择的新辅助化疗后前哨淋巴结阳性患者,省略完成性腋窝淋巴结清扫而以未清扫腋窝照射替代,不损害局部、区域或远处控制及总生存,且淋巴水肿发生率更低。
研究设计与样本
- 采用Kaplan-Meier法分析局部、区域、远处复发及总生存,Cox回归分析预测因素。
主要发现
- 中位随访28.8个月(范围2.5-137.0)。
- 9例(5.6%)区域复发作为首次复发的一部分,其中5例累及腋窝1或2站,6例累及腋窝3站或锁骨上淋巴结,2例累及内乳淋巴结,部分患者多区域受累。
- 腋窝清扫范围(仅前哨淋巴结活检对比加腋窝清扫)未预测疾病控制或生存。
临床怎么用
- 对新辅助化疗后前哨淋巴结阳性的乳腺癌患者,可考虑省略完成性腋窝淋巴结清扫,以区域淋巴结照射替代,以降低淋巴水肿风险。
- 需仔细选择患者,确保未清扫腋窝接受完整区域照射。
局限性
- 回顾性研究设计,样本量161例,中位随访28.8个月较短。
- 未报告放疗剂量、靶区范围及患者选择标准等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current standard of care for patients with breast cancer with a positive node on sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy is axillary dissection with irradiation of the regional nodes, but it is unknown whether axillary lymph node dissection (ALND) can be safely omitted if complete axillary radiation is delivered instead. METHODS AND MATERIALS: We identified 161 patients found to have a positive sentinel lymph node on SLNB after neoadjuvant chemotherapy for breast cancer between December 2006 and October 2017, who were treated with or without completion ALND. Local, regional, and distant recurrence and overall survival were analyzed using the Kaplan-Meier method. Patient, disease, and treatment factors potentially predictive of each outcome were entered into Cox regression analysis. RESULTS: Median follow-up was 28.8 months (range, 2.5-137.0). The 3-year regional control rate did not differ according to extent of axillary surgery (92.6% for SLNB alone vs 96.4% for SLNB with ALND, P = .616). Regional recurrence occurred as part of first recurrence in 9 patients (5.6%). Five patients failed in axillary levels 1 or 2, 6 failed in axillary level 3 or supraclavicular nodes, and 2 failed in internal mammary nodes, with some patients failing in multiple regional nodal areas. Extent of axillary dissection (SLNB only vs SLNB plus ALND) did not predict for disease control or survival. Patients who underwent ALND were significantly more likely to have lymphedema (25.0% vs 9.4%, P = .021). CONCLUSIONS: Careful selection of patients with a positive sentinel node on SLNB after neoadjuvant chemotherapy for omission of completion ALND in favor of irradiation of the undissected axilla does not compromise local, regional, or distant control or overall survival and results in lower rates of lymphedema.
引用
- Ling DC, Iarrobino NA, Champ CE, et al. Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy. Adv Radiat Oncol. 2019. PMID: 32280815. doi:10.1016/j.adro.2019.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。